tiprankstipranks
Advertisement
Advertisement

XENE Stock Latest News

Xenon Pharmaceuticals price target lowered to $63 from $64 at Wedbush
The FlyXenon Pharmaceuticals price target lowered to $63 from $64 at Wedbush
20d ago
XENE
Xenon Sets Date for 2026 Annual Shareholder Meeting
PremiumCompany Announcements
Xenon Sets Date for 2026 Annual Shareholder Meeting
23d ago
8K
XENE
Xenon’s X-TOLE2 Trial Completion Puts XEN1101 in Focus for Epilepsy Investors
PremiumCompany Announcements
Xenon’s X-TOLE2 Trial Completion Puts XEN1101 in Focus for Epilepsy Investors
23d ago
XENE
Xenon Strengthens Balance Sheet With Major Equity Offering
PremiumCompany Announcements
Xenon Strengthens Balance Sheet With Major Equity Offering
24d ago
8K
XENE
Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00
PremiumThe Fly
Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00
25d ago
XENE
Xenon Raises $650 Million in Upsized U.S. Equity Offering
PremiumCompany AnnouncementsXenon Raises $650 Million in Upsized U.S. Equity Offering
26d ago
XENE
Xenon Pharmaceuticals: Buy Rating Backed by Superior X-TOLE2 Phase 3 Results and Commercial Upside for Azetukalner in Focal Epilepsy
Premium
Ratings
Xenon Pharmaceuticals: Buy Rating Backed by Superior X-TOLE2 Phase 3 Results and Commercial Upside for Azetukalner in Focal Epilepsy
26d ago
XENE
Xenon Pharmaceuticals price target raised to $64 from $47 at Wedbush
Premium
The Fly
Xenon Pharmaceuticals price target raised to $64 from $47 at Wedbush
26d ago
XENE
Xenon Pharmaceuticals price target raised to $90 from $60 at Guggenheim
PremiumThe Fly
Xenon Pharmaceuticals price target raised to $90 from $60 at Guggenheim
26d ago
XENE
Xenon Pharmaceuticals price target raised to $68 from $49 at Wells Fargo
PremiumThe Fly
Xenon Pharmaceuticals price target raised to $68 from $49 at Wells Fargo
26d ago
XENE
Biohaven price target raised to $27 from $24 at Goldman Sachs
PremiumThe Fly
Biohaven price target raised to $27 from $24 at Goldman Sachs
26d ago
BHVN
XENE
Xenon Pharmaceuticals price target raised to $75 from $52 at Goldman Sachs
PremiumThe Fly
Xenon Pharmaceuticals price target raised to $75 from $52 at Goldman Sachs
26d ago
XENE
Xenon Pharmaceuticals price target raised to $74 from $53 at H.C. Wainwright
PremiumThe FlyXenon Pharmaceuticals price target raised to $74 from $53 at H.C. Wainwright
26d ago
XENE
Xenon Pharmaceuticals price target raised to $90 from $56 at Deutsche Bank
Premium
The Fly
Xenon Pharmaceuticals price target raised to $90 from $56 at Deutsche Bank
26d ago
XENE
Xenon Pharmaceuticals Launches $500 Million Public Share Offering
Premium
Company Announcements
Xenon Pharmaceuticals Launches $500 Million Public Share Offering
27d ago
XENE
Xenon Pharmaceuticals announces $500M common shares offering
PremiumThe Fly
Xenon Pharmaceuticals announces $500M common shares offering
27d ago
XENE
Xenon Pharmaceuticals price target raised to $100 from $65 at Jefferies
PremiumThe Fly
Xenon Pharmaceuticals price target raised to $100 from $65 at Jefferies
27d ago
XENE
Xenon Pharmaceuticals price target raised to $80 from $59 at RBC Capital
PremiumThe Fly
Xenon Pharmaceuticals price target raised to $80 from $59 at RBC Capital
27d ago
XENE
Raymond James says rival readout gives Biohaven’s Opakalim room to differentiate
PremiumThe Fly
Raymond James says rival readout gives Biohaven’s Opakalim room to differentiate
27d ago
BHVN
XENE
Xenon Pharmaceuticals: Blockbuster Potential for Azetukalner After Outperforming Phase 3 Epilepsy Data Drives Target Hike to $80
PremiumRatingsXenon Pharmaceuticals: Blockbuster Potential for Azetukalner After Outperforming Phase 3 Epilepsy Data Drives Target Hike to $80
27d ago
XENE
Xenon Pharmaceuticals: Azetuklaner’s Strong Phase III Data and Blockbuster Potential Underscore Undervalued Buy Opportunity
Premium
Ratings
Xenon Pharmaceuticals: Azetuklaner’s Strong Phase III Data and Blockbuster Potential Underscore Undervalued Buy Opportunity
27d ago
XENE
Xenon Pharmaceuticals price target raised to $97 from $63 at Baird
Premium
The Fly
Xenon Pharmaceuticals price target raised to $97 from $63 at Baird
27d ago
XENE

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >